PPID horses may live as long, but with more medical events

A new study is reshaping the conversation around pituitary pars intermedia dysfunction in horses: PPID may not shorten lifespan, but it does seem to make later life medically busier. In a recent JAVMA paper highlighted by AVMA’s Veterinary Vertex podcast, researchers reported that horses diagnosed with PPID did not have shorter life expectancy than matched controls, despite experiencing more medical events over time. That’s a notable shift from the more fatalistic framing that can still surround the diagnosis in practice. (pubmed.ncbi.nlm.nih.gov)

The work came from Purdue investigators Emma Stapley, Caroline Gillespie-Harmon, Sarah Waxman, Amanda Farr, and François-René Bertin. According to the podcast discussion, the team deliberately built a primary-care dataset rather than relying on referral-hospital cases, which often skew toward more severe disease and more resourced clients. Controls were matched by age, breed type, and pet parent, an unusual design choice intended to account for management style, willingness to test, and socioeconomic differences that can influence how often disease is recognized and treated. (pubmed.ncbi.nlm.nih.gov)

That design matters because PPID is common in older horses, and its signs can overlap with what some pet parents and even barns dismiss as “just aging.” In the podcast, Bertin emphasized that PPID in horses is no longer simply lumped under “Cushing’s disease,” because the pathophysiology differs from the canine and human forms and is thought to be more closely tied to neurodegenerative dopaminergic change. Clinically, though, veterinarians still see the familiar picture: older horses with abnormal haircoat, sweating, recurrent infections, lameness, and laminitis risk. (veterinaryvertex.buzzsprout.com)

The study’s key finding was the split between survival and morbidity. In the associated ACVIM abstract and podcast discussion, PPID cases had more adverse medical events overall, with significant differences in hyperinsulinemia-associated laminitis, poor healing, NSAID prescribing, and dental abnormalities including missing teeth or EOTRH-related findings. The authors reviewed 2,914 medical events across 406 horses, suggesting that while these horses may live just as long, they often require more clinical attention during that time. (academic.oup.com)

That aligns with earlier PPID literature, but also refines it. A 2012 long-term prognosis study found that 50% of horses survived about 4.5 years after diagnosis and that most pet parents were satisfied enough with quality of life to say they would treat another horse with PPID. More recent work on pergolide has similarly suggested durable improvement in clinical signs and, in some cases, endocrine control over years of treatment. Together, those findings support the idea that PPID is increasingly manageable, even if it remains a chronic, progressive disorder. (pubmed.ncbi.nlm.nih.gov)

The expert perspective from the Veterinary Vertex interview was notably practical. Bertin said the take-home message for veterinarians is to test and treat, not to assume PPID is a “death sentence.” He also suggested some of the higher event rate may reflect better observation rather than only worse disease: horses receiving daily pergolide and closer attention from pet parents may have subtle problems recognized sooner, from nasal discharge to eye issues to early laminitic change. That interpretation is an inference from the study context, but it’s a clinically plausible one, especially in ambulatory practice where detection depends heavily on day-to-day observation. (veterinaryvertex.buzzsprout.com)

Why it matters: For veterinary professionals, this study supports a more nuanced care model for older horses. Prognosis conversations can be more reassuring, but they should also be more explicit about workload: PPID management means ongoing endocrine monitoring, attention to insulin dysregulation and laminitis, and probably a lower threshold to investigate wound healing and dental changes. The dental signal is especially worth watching because it hints at a broader comorbidity profile that may not yet be fully understood. In practice, this reinforces the value of routine screening in older horses and of framing treatment as longitudinal care, not a single prescription. (veterinaryvertex.buzzsprout.com)

What to watch: The next step is likely more granular work on causation, including whether some “extra” medical events are direct consequences of PPID biology, consequences of associated insulin dysregulation, or simply the result of closer monitoring in treated horses; the Purdue team also flagged dental disease and aging-related mechanisms as areas for follow-up. (veterinaryvertex.buzzsprout.com)